Orgenesis Stock Net Income
| ORGS Stock | USD 0.60 0.45 300.00% |
As of the 30th of January, Orgenesis holds the Risk Adjusted Performance of 0.2219, semi deviation of 30.29, and Coefficient Of Variation of 342.59. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Orgenesis, as well as the relationship between them. Please check Orgenesis downside deviation, jensen alpha, as well as the relationship between the Jensen Alpha and downside variance to decide if Orgenesis is priced some-what accurately, providing market reflects its current price of 0.6 per share. As Orgenesis is a penny stock we also suggest to check out its total risk alpha numbers.
Orgenesis' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Orgenesis' valuation are provided below:Orgenesis does not presently have any trending fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Orgenesis |
Orgenesis 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Orgenesis' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Orgenesis.
| 11/01/2025 |
| 01/30/2026 |
If you would invest 0.00 in Orgenesis on November 1, 2025 and sell it all today you would earn a total of 0.00 from holding Orgenesis or generate 0.0% return on investment in Orgenesis over 90 days. Orgenesis is related to or competes with Helix BioMedix. Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide More
Orgenesis Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Orgenesis' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Orgenesis upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 52.08 | |||
| Information Ratio | 0.2914 | |||
| Maximum Drawdown | 512.08 | |||
| Value At Risk | (75.71) | |||
| Potential Upside | 341.18 |
Orgenesis Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Orgenesis' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Orgenesis' standard deviation. In reality, there are many statistical measures that can use Orgenesis historical prices to predict the future Orgenesis' volatility.| Risk Adjusted Performance | 0.2219 | |||
| Jensen Alpha | 36.24 | |||
| Total Risk Alpha | 26.97 | |||
| Sortino Ratio | 0.6824 | |||
| Treynor Ratio | (2.81) |
Orgenesis January 30, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.2219 | |||
| Market Risk Adjusted Performance | (2.80) | |||
| Mean Deviation | 81.61 | |||
| Semi Deviation | 30.29 | |||
| Downside Deviation | 52.08 | |||
| Coefficient Of Variation | 342.59 | |||
| Standard Deviation | 121.97 | |||
| Variance | 14877.32 | |||
| Information Ratio | 0.2914 | |||
| Jensen Alpha | 36.24 | |||
| Total Risk Alpha | 26.97 | |||
| Sortino Ratio | 0.6824 | |||
| Treynor Ratio | (2.81) | |||
| Maximum Drawdown | 512.08 | |||
| Value At Risk | (75.71) | |||
| Potential Upside | 341.18 | |||
| Downside Variance | 2712.36 | |||
| Semi Variance | 917.2 | |||
| Expected Short fall | (195.01) | |||
| Skewness | 2.08 | |||
| Kurtosis | 3.36 |
Orgenesis Backtested Returns
Orgenesis is out of control given 3 months investment horizon. Orgenesis maintains Sharpe Ratio (i.e., Efficiency) of 0.29, which implies the firm had a 0.29 % return per unit of risk over the last 3 months. We were able to analyze and collect data for twenty-eight different technical indicators, which can help you to evaluate if expected returns of 36.2% are justified by taking the suggested risk. Use Orgenesis Coefficient Of Variation of 342.59, semi deviation of 30.29, and Risk Adjusted Performance of 0.2219 to evaluate company specific risk that cannot be diversified away. Orgenesis holds a performance score of 23 on a scale of zero to a hundred. The company holds a Beta of -12.65, which implies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Orgenesis are expected to decrease by larger amounts. On the other hand, during market turmoil, Orgenesis is expected to outperform it. Use Orgenesis sortino ratio and the relationship between the downside variance and period momentum indicator , to analyze future returns on Orgenesis.
Auto-correlation | -0.09 |
Very weak reverse predictability
Orgenesis has very weak reverse predictability. Overlapping area represents the amount of predictability between Orgenesis time series from 1st of November 2025 to 16th of December 2025 and 16th of December 2025 to 30th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Orgenesis price movement. The serial correlation of -0.09 indicates that less than 9.0% of current Orgenesis price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.09 | |
| Spearman Rank Test | -0.05 | |
| Residual Average | 0.0 | |
| Price Variance | 0.02 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Orgenesis reported net income of (64.92 Million). This is 119.02% lower than that of the Biotechnology sector and 192.68% lower than that of the Health Care industry. The net income for all United States stocks is 111.37% higher than that of the company.
Orgenesis Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Orgenesis' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Orgenesis could also be used in its relative valuation, which is a method of valuing Orgenesis by comparing valuation metrics of similar companies.Orgenesis is currently under evaluation in net income category among its peers.
Orgenesis Fundamentals
| Return On Equity | -7.27 | |||
| Return On Asset | -0.3 | |||
| Operating Margin | (16.54) % | |||
| Current Valuation | 23.01 M | |||
| Shares Outstanding | 4.77 M | |||
| Shares Owned By Insiders | 21.16 % | |||
| Shares Owned By Institutions | 4.54 % | |||
| Number Of Shares Shorted | 56.25 K | |||
| Price To Earning | 7.52 X | |||
| Price To Book | 1.26 X | |||
| Price To Sales | 15.21 X | |||
| Revenue | 530 K | |||
| Gross Profit | 36.02 M | |||
| EBITDA | (54.07 M) | |||
| Net Income | (64.92 M) | |||
| Cash And Equivalents | 2.3 M | |||
| Cash Per Share | 0.09 X | |||
| Total Debt | 22.62 M | |||
| Debt To Equity | 0.64 % | |||
| Current Ratio | 1.57 X | |||
| Book Value Per Share | (3.30) X | |||
| Cash Flow From Operations | (14.84 M) | |||
| Short Ratio | 2.39 X | |||
| Earnings Per Share | (8.00) X | |||
| Target Price | 6.0 | |||
| Number Of Employees | 146 | |||
| Beta | 1.21 | |||
| Market Capitalization | 10.07 M | |||
| Total Asset | 14.55 M | |||
| Retained Earnings | (176.62 M) | |||
| Working Capital | (12.33 M) | |||
| Current Asset | 5.29 M | |||
| Current Liabilities | 14.92 M | |||
| Net Asset | 14.55 M |
About Orgenesis Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Orgenesis's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Orgenesis using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Orgenesis based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Orgenesis Pink Sheet Analysis
When running Orgenesis' price analysis, check to measure Orgenesis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orgenesis is operating at the current time. Most of Orgenesis' value examination focuses on studying past and present price action to predict the probability of Orgenesis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Orgenesis' price. Additionally, you may evaluate how the addition of Orgenesis to your portfolios can decrease your overall portfolio volatility.